A clinical stage business, developing theranostics for rare cancers.
A Centocor spinoff, we’re rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding scientific network.
In clinical development:
EBTATE (177Lu-EBTATE) A long lived radiotherapeutic for gastroenteropancreatic neuroendocrine and Hürthle cell thyroid tumors (under license from the NIH) Early human testing showed EBTATE is safe and more effective than competitors. US trials begin in Q4 2021 at Memorial Sloan Kettering Cancer Center.
EBRGD (177Lu-EBRGD) A long-lived radiotherapeutic for αvβ3 expressing tumors. We're targeting glioblastoma multiforme and non-small cell lung cancer. (under license from the NIH). Trials planned in 2022.
FGA (18F-fluoroglucaric acid) A PET radiodiagnostic targeting histones released during necrosis and cell death. Focused on tumor response to chemotherapy of brain and lung cancers.
TDURA (99mTc-duramycin) A SPECT radiodiagnostic targeting phosphatidylethanolamine, exposed on cell surfaces during cell death. Focused on very early visualization of tumor death during chemotherapy, distinguishing responders from non-responders in one day. Phase 0/I trials in colorectal tumor response to therapy underway at the University of Antwerp.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 833 Lincoln Ave,
- Phone
- +1 610-738-7928
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mtarget.com
- Keywords
- imaging, diagnostics, radiodiagnostics, radiotherapeutics, biomarkers, ocular imaging, cell imaging, neural imaging, cancer, cardiac, colorectal, licensing, neuroendocrine, glioblastoma, radioimaging, PET, SPECT, brain cancer, lung cancer, collaboration.
- HQ
- West Chester, Pennsylvania
Molecular Targeting Technologies,inc Questions
Molecular Targeting Technologies,Inc's helpline number is +1 610-738-7928
Molecular Targeting Technologies,Inc's website is mtarget.com
Molecular Targeting Technologies,Inc's LinkedIn profile is https://www.linkedin.com/company/molecular-targeting-technologies-inc
Molecular Targeting Technologies,Inc has
7 employees.
View email and phone details for 7
employees at Molecular Targeting Technologies,Inc.
Molecular Targeting Technologies,Inc's industry is
Pharmaceutical Manufacturing
Molecular Targeting Technologies,Inc's top competitors are
Vertex Pharmaceuticals,
Evathera Theranostics,
Evergreen Theragnostics,
Voximetry,
Molecular Targeting Technology, Inc.,
Lehigh University Community Service Office,
Alpha-9 Oncology,
Regeneron,
Prostat Healthcare Inc.,
Abdera Therapeutics.
Molecular Targeting Technologies,Inc's categories are Pharmaceutical Manufacturing
Molecular Targeting Technologies,Inc's founding year is 2011
